US · EYPT
EyePoint Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Watertown, MA 02472
- Website
- eyepointpharma.com
Price · as of 2024-12-31
$13.34
Market cap 1.45B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,632.25 | +12,135.76% |
| Intrinsic Value(DCF) | $4.41 | -66.94% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $34.30 | $1,559.02 | $5.17 | $41.73 | $446.26 |
| 2011 | $44.30 | $871.89 | $10.99 | $0.00 | $296.00 |
| 2012 | $17.60 | $114.21 | $0.00 | $0.00 | $234.23 |
| 2013 | $37.90 | $46.37 | $0.00 | $0.00 | $151.64 |
| 2014 | $47.80 | $42.02 | $0.00 | $0.00 | $0.00 |
| 2015 | $37.10 | $1,206.15 | $999.81 | $18.76 | $1,391.81 |
| 2016 | $37.00 | $1,053.48 | $0.00 | $0.00 | $557.24 |
| 2017 | $12.80 | $50.88 | $333.06 | $0.00 | $0.00 |
| 2018 | $22.20 | $19.32 | $0.00 | $0.00 | $575.42 |
| 2019 | $12.80 | $81.49 | $1,127.48 | $0.00 | $0.00 |
| 2020 | $11.21 | $78.33 | $1,985.33 | $0.00 | $0.00 |
| 2021 | $13.19 | $33.05 | $1,455.66 | $0.00 | $0.00 |
| 2022 | $2.42 | $18.18 | $1.78 | $0.00 | $0.00 |
| 2023 | $24.40 | $50.99 | $5.12 | $0.00 | $0.00 |
| 2024 | $7.13 | $1,632.25 | $2.92 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates EyePoint Pharmaceuticals, Inc.'s (EYPT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,632.25
- Current price
- $13.34
- AI upside
- +12,135.76%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.41
-66.94% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EYPT | EyePoint Pharmaceuticals,… | $13.34 | 1.45B | +12,136% | -67% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| BCAX | Bicara Therapeutics Inc. … | $16.78 | 919.24M | — | — | — | — | -13.25 | 1.83 | — | -5.00 | -52.99 | 1.83 | 0.00% | — | — | -19.14% | 1967.97% | -16.93% | 0.00 | — | 27.93 | 27.22 | 5.94 | 2500.00% | — | 6190.00% | -8.31% | -4.16 | 1787.22% | 0.00% | 0.00% | 28.78% | -5.00 | -5.50 | — | 6.99 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| NRIX | Nurix Therapeutics, Inc. | $15.97 | 1.38B | +65% | -49% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| PRME | Prime Medicine, Inc. | $4.62 | 833.96M | — | -79% | — | — | -1.45 | 1.86 | 95.42 | -0.69 | — | 1.86 | 100.00% | -6787.36% | -6566.61% | -136.88% | -1418.83% | -79.73% | 0.27 | — | 5.58 | 5.02 | 0.72 | -2417.00% | — | -2525.00% | -45.73% | -3.24 | -912.12% | 0.00% | 0.00% | 39.96% | -0.67 | -1.04 | 45.25 | -3.59 |
| PROK | ProKidney Corp. | $2.24 | 277.76M | — | — | — | — | -0.63 | -0.10 | 1352.79 | 1.59 | -7.18 | -0.10 | 100.00% | -241678.95% | -80507.89% | 15.57% | 13.02% | -37.91% | 0.00 | -20408.44 | 10.93 | 9.96 | 0.60 | 877.00% | — | 2542.00% | -151.60% | -3.49 | 11.09% | 0.00% | 0.00% | 38.56% | 1.37 | 1.62 | -3319.00 | -2.64 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| SEPN | Septerna, Inc. | $29.02 | 1.3B | +1,403% | -60% | -79% | — | -0.89 | 0.15 | 59.16 | 3.30 | — | 0.15 | 100.00% | -7518.42% | -6678.88% | -37.62% | 815.26% | -24.45% | 0.06 | — | 27.77 | 27.40 | 2.68 | -2504845.00% | 61192.00% | 6724.00% | -109.39% | -5.25 | 706.65% | 0.00% | 0.00% | 215.10% | 3.24 | 3.76 | -243.58 | 1.00 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
- CEO
- Jay S. Duker
- Employees
- 165
- Beta
- 1.79
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.41 ÷ $13.34) − 1 = -66.94% (DCF, example).